Avacta is a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative, proprietary Affimer® and pre|CISION™ platforms
Avacta Life Sciences has two divisions; therapeutics and diagnostics.
Avacta’s therapeutics division, based in White City, London, U.K. develops novel cancer immunotherapies combining its two proprietary platforms – Affimer® biotherapeutics and pre|CISIONTM tumour targeted chemotherapy. With this approach, the Company aims to address the lack of a durable response to current immunotherapies experienced by most patients.
The Affimer® platform is a novel class of biotherapeutic based on a naturally occurring human protein. It is Avacta’s proprietary therapeutic platform with its intellectual property covered by several patent families.
Avacta’s proprietary pre|CISIONTM targeted chemotherapy platform, releases active drug only in the tumour, thereby limiting systemic exposure and improving the overall safety and therapeutic potential of these powerful anti-cancer treatments. Avacta took its first pre|CISIONTM drug candidate AVA6000, a targeted form of the standard-of-care Doxorubicin, into the clinic in summer 2021.
By combining these two platforms the Company is building a pipeline of novel cancer therapies with the aim of creating effective treatments for all cancer patients including those who do not respond to existing immunotherapies.
Avacta’s diagnostics division, based in Wetherby, UK., utilises it’s proprietary Affimer® platform to develop high performing diagnostics and works with partners world-wide to develop Affimer reagents with the objective of establishing royalty bearing license deals.
The Affimer® platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets worth in excess of $100bn. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken, and the reliance on an animal’s immune response, to generate new antibodies; poor specificity in many cases; large size and cost.
“What drives us all at Avacta is the opportunity to realise the incredible potential of the Affimer and pre|CISION platforms to create new tools for life sciences and, in our own drug development programmes, to make a measurable difference to patients lives through clinically superior cancer immunotherapies.”